短期给予HIV蛋白酶抑制剂沙奎那韦通过增强破骨细胞生成改善颅骨愈合
研究在小鼠颅骨缺损模型中评估短期给予沙奎那韦对颅骨愈合的影响,并通过体外实验探讨其对细胞活力、迁移及成骨/破骨分化的作用。结果显示1周沙奎那韦给药改善了颅骨愈合,伴随破骨细胞浸润和M2巨噬细胞浸润增加,以及RANKL等基因表达升高。作者认为短期沙奎那韦改善颅骨修复可能涉及增强破骨细胞生成和调节损伤后炎症反应,并可能被重新用于骨骼修复。
要点
- 小鼠颅骨缺损模型中,1周沙奎那韦给药改善了颅骨愈合。
- 沙奎那韦在体内第7天增强破骨细胞浸润,并增加CD206+ M2巨噬细胞浸润。
- 体外高浓度沙奎那韦抑制MC3T3-E1细胞活力,但未影响迁移或矿化。
核心结论
- 短期沙奎那韦治疗改善颅骨骨修复可能涉及增强破骨细胞生成和调节颅骨损伤后的炎症反应。
研究设计与样本
- 采用小鼠颅骨缺损模型,通过基因表达、组织学、免疫组化和断层扫描评估沙奎那韦对颅骨愈合的影响。
- 体外评估沙奎那韦对细胞活力、迁移及成骨和破骨分化的作用。
主要发现
- 基于微型计算机断层扫描和组织形态计量学分析,1周沙奎那韦给药改善了颅骨骨愈合。
- 与载体对照相比,1周沙奎那韦治疗在day 7增强破骨细胞浸润(抗酒石酸酸性磷酸酶染色),但在days 14和28未增强。
- 与载体对照相比,1周沙奎那韦治疗在days 7、14和28诱导更多CD206+ M2巨噬细胞浸润,但未增加F4/80+ M0巨噬细胞。
- 1周沙奎那韦治疗升高了破骨细胞生成基因RANKL(定量聚合酶链反应)表达及其他成骨和细胞因子表达。
- 体外数据显示沙奎那韦给药未影响MC3T3-E1细胞迁移或矿化,而较高浓度沙奎那韦抑制细胞活力。
临床怎么用
- 作者认为沙奎那韦可能被重新用于骨骼修复。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Using immunomodulatory methods to address the challenging issue of craniofacial bone repair may be a potentially effective approach. The protease inhibitor saquinavir has been shown to inhibit the inflammatory response by targeting the toll-like receptor 4/myeloid differentiation primary response complex. Independently, inhibition of toll-like receptor 4 or myeloid differentiation primary response led to enhanced skull bone repair. Therefore, the authors aimed to investigate the effects of saquinavir on skull bone healing. METHODS: The effects of saquinavir on skull bone healing were assessed by means of gene expression, histology, immunohistochemistry, and tomography in a mouse calvarial defect model. Subsequently, the role of saquinavir in cell viability, migration, and osteogenic and osteoclastogenic differentiation was also evaluated in vitro. RESULTS: One-week saquinavir administration improved skull bone healing based on micro-computed tomographic and histomorphometric analyses. Compared to the vehicle control, 1-week saquinavir treatment (1) enhanced osteoclast infiltration (tartrate-resistant acid phosphatase staining) at day 7, but not at days 14 and 28; (2) induced more CD206 + M2 macrophage infiltration, but not F4/80 + M0 macrophages at days 7, 14, and 28; and (3) elevated osteoclastogenic gene RANKL (quantitative polymerase chain reaction) expression and other osteogenic and cytokine expression. Furthermore, in vitro data showed that saquinavir administration did not influence MC3T3-E1 cell migration or mineralization, whereas higher concentrations of saquinavir inhibited cell viability. Saquinavir treatment also enhanced the osteoclastic differentiation of bone marrow-derived precursors, and partially reversed high-mobility group box 1-driven osteoclastogenesis inhibition and elevated proinflammatory cytokine expression. CONCLUSION: The improved skull bone repair following short-term saquinavir treatment may involve enhanced osteoclastogenesis and modulated inflammatory response following skull injury. CLINICAL RELEVANCE STATEMENT: The authors' work demonstrates improved skull bone healing by short-term application of saquinavir, a drug traditionally used in the treatment of acquired immunodeficiency syndrome. As such, saquinavir may be repurposed for skeletal repair.
引用
- Liu H, Shen Y, Zhao B, et al. Short-Term Administration of HIV Protease Inhibitor Saquinavir Improves Skull Bone Healing with Enhanced Osteoclastogenesis. Plast Reconstr Surg. 2022. PMID: 36112847. doi:10.1097/PRS.0000000000009734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。